CN108179152A - A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin - Google Patents
A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin Download PDFInfo
- Publication number
- CN108179152A CN108179152A CN201711469025.6A CN201711469025A CN108179152A CN 108179152 A CN108179152 A CN 108179152A CN 201711469025 A CN201711469025 A CN 201711469025A CN 108179152 A CN108179152 A CN 108179152A
- Authority
- CN
- China
- Prior art keywords
- recombinant protein
- people
- epitope
- fibronectin
- type structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 102000036639 antigens Human genes 0.000 title claims abstract description 30
- 108091007433 antigens Proteins 0.000 title claims abstract description 30
- 239000000427 antigen Substances 0.000 title claims abstract description 29
- 108010067306 Fibronectins Proteins 0.000 title claims abstract description 28
- 230000009977 dual effect Effects 0.000 title claims abstract description 17
- 102000016359 Fibronectins Human genes 0.000 title claims abstract 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 230000006798 recombination Effects 0.000 claims abstract description 10
- 230000004927 fusion Effects 0.000 claims abstract description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 52
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 51
- 241000588724 Escherichia coli Species 0.000 claims description 23
- 239000013604 expression vector Substances 0.000 claims description 17
- 230000003834 intracellular effect Effects 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 238000005215 recombination Methods 0.000 claims description 5
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 4
- -1 isopropylthio Chemical group 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000411 inducer Substances 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000012215 gene cloning Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 102000037865 fusion proteins Human genes 0.000 abstract description 2
- 108020001507 fusion proteins Proteins 0.000 abstract description 2
- 241000588722 Escherichia Species 0.000 abstract 1
- 102100037362 Fibronectin Human genes 0.000 description 20
- 239000002585 base Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 102400001263 NT-proBNP Human genes 0.000 description 14
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 13
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 10
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 10
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 229940041514 candida albicans extract Drugs 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000012137 tryptone Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101000589010 Homo sapiens Myomesin-1 Proteins 0.000 description 2
- 101000589013 Mus musculus Myomesin-1 Proteins 0.000 description 2
- 102100032971 Myomesin-1 Human genes 0.000 description 2
- 102100036836 Natriuretic peptides B Human genes 0.000 description 2
- 101710187802 Natriuretic peptides B Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 101800001904 NT-proBNP Proteins 0.000 description 1
- 101800001442 Peptide pr Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention discloses a kind of method that III type structural domain (Fn3) two epitopes of displaying of people's fibronectin is applied to be used to prepare antigen substitute.Two epitope base sequences of coding for antigens are binned in the FG loop areas and 3 ' ends of coding Fn3 gene orders, form Fn3 and dual anti-former epitope fusion gene by this method respectively by genetic recombination.The fusion protein of the double epitopes of Fn3 displayings efficiently, is rapidly expressed and prepared using escherichia expression system.The beneficial effects of the invention are as follows can simply, quickly, efficiently prepare with the antigen substitute for showing pair epitopes, to produce corresponding immunology detection establishing techniques platform.
Description
Technical field
It is specifically a kind of to be based on people's fibronectin III the invention belongs to genetic engineering field and protein engineering field
The method that the dual anti-former epitope of type structure domain views prepares antigen substitute.
Background technology
III type structural domain (abbreviation Fn3) of people's fibronectin be one kind be resistant to multiple amino acid be inserted into, missing or
It replaces and keeps the skelemin that it is folded and tertiary structure is constant, have the characteristics that stability is high, soluble high, it can be in large intestine
High level expression in bacillus.Independent folding unit small as one Fn3, without cysteine and disulfide bond, by four β-foldings
A folded and alpha-helix forms；Three loop regions (BC loop areas, DE loop areas and FG loop are formed between its segment
Area).Show that FGloop areas have higher flexibility through numerous studies, be mutated or lack the structure for skelemin Fn3
It is little with stability influence.In addition, Fn3 also has very high thermal stability (Tm values are up to 87 DEG C)；Under room temperature, in pH
Remain to keep the native conformation of protein in the range of value 2-11.3.The design feature of Fn3 is stable to be synthesized based on it
Made binding proteins provide good condition, are highly suitable as fusion protein and are purified in expression in escherichia coli.More than it is special
Point is provides possibility based on the dual anti-former epitope of III type structure domain views of people's fibronectin.
Epitope (Antigenic epitope), also known as antigenic determinant (Antigenic determinant, AD),
Refer to the special chemical group that antigentic specificity is determined in antigen molecule.Epitope typically refers to its of the substances such as extraneous protein
Middle a part of sequence.It is normally only made of for the epitope of proteinaceous antigen several to more than ten amino acid.It is applying
When enzyme-linked immunosorbent assay (abbreviation ELISA) detects proteinaceous antigen content, need detected proteantigen and make
For reference substance, double antibody sandwich method is usually taken to be detected.One of antibody is fixed on solid table as capture antibody
Face；Another antibody enzyme or fluorescent marker, as detection antibody.Proteinaceous antigen, particularly small-molecule peptide are universal
There are unstable, easily degrade, the features such as manufacturing cost is higher.Such as plasma pro-brain natriuretic peptide levels N-terminal portion (N-terminal pro-
Brain natriuretic peptide, NT-proBNP) it is cardiac muscle cell in synthesis polypeptide parahormone Type B brain natriuretic peptide (BNP)
Straight-chain polypeptide segment inactive, being made of 76 amino acid generated in the process.In patients with heart failure blood BNP and
The concentration of two kinds of polypeptides of NT-proBNP is directly proportional to heart failure severity, and patients with heart failure plasma BNP concentrations can increase to several ng/
ML, and NT-ProBNP may be up to tens ng/mL.NT-proBNP biological half-lifes are 60-120 minutes, are partly declined compared to biology
Phase is only the more of the BNP long of 20 minutes, and it is a specificity mark for measuring heart failure to have been recognized that NT-ProBNP in the world at present
Will object.But polypeptide NT-proBNP, as antigen marker, molecular weight is small (76 amino acid), only 8.45kD, and unstable
Fixed, separation and purifying difficulty are also big while degradable.It is therefore desirable to by genetic recombination mode, encoding target is protein-based
Double epitope sequences are binned in a stable protein gene sequence, such as Fn3 is highly stable protein, is utilized
Escherichia coli can the great expression stable protein, by target protein epitope display on stable Fn3 recombinant proteins, as
Corresponding proteantigen substitute has important researching value.
The present invention is using III type structural domain (Fn3) of people's fibronectin, by showing plasma pro-brain natriuretic peptide levels N-terminal NT-
The bis- epitopes of proBNP, efficiently the stable antigen protein substitute of production, provides and solves the difficult side of proteinaceous antigen preparation
Method provides effective way to prepare immunology detection standard items.
Invention content
The present invention provides a kind of based on III type knot of people's fibronectin to solve the problems, such as that prepared by proteinaceous antigen difficult
The method that the double epitopes of structure domain views prepare antigen substitute provides effective way to prepare immunology detection standard items.
For achieving the above object, the present invention uses following technical scheme：
A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin,
It is characterized in that, the described method comprises the following steps：
(1) by genetic recombination, structure can be double in III type structure domain views of expression in escherichia coli people fibronectin
The recombinant protein expression vector of epitope；
(2) the recombinant protein expression vector built in step (1) is converted into colibacillus engineering strain, filters out positive turn
Beggar；
(3) positive transformant for filtering out step (2) carries out expression and purity, recombinant protein needed for acquisition.
The above method is further included carries out double antibody sandwich ELISA detection to the recombinant protein that step (3) obtains.
Further, step (1) detailed process is：By the base sequence of coding for antigens epitope, plasma pro-brain natriuretic peptide levels N is such as encoded
The base sequence (NT-proBNP12-21 epitopes) of the amino acid of 12-21 is held, replaces III type structural domain of people's fibronectin
The base sequence (base sequence of coding Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys) in FG loop areas is encoded, and
Another epitope base sequence will be encoded, such as encodes the base sequence (NT- of the amino acid of plasma pro-brain natriuretic peptide levels N-terminal 62-73
ProBNP62-73 epitopes), by encode SSNNNNNNNNNN small peptides be binned in more than gene 3 ' end.It is residual that S represents serine
Base, N represent asparagine residue.In 5 ' end recombination 6 histidine tags of coding of more than fusion, reflect for recombinant protein
Determine and isolate and purify.Restriction enzyme site Nco I and Hind III is introduced respectively at 5 ' ends and 3 ' ends simultaneously.By more than fusion enzyme
Enzyme site Nco I and Hind III is building up on pET28 intracellular expression vector of Escherichia coli to get to recombinant protein expression vector.
Further, the recombinant protein expression vector conversion colibacillus engineering strain obtained in step (2), using containing anti-
The LB solid medium flat screens of raw element select positive transformant.
Further, step (3) detailed process is：The positive transformant that step (2) is filtered out, in LB fluid nutrient mediums
It is middle to cultivate to OD600nmWhen=0.4~0.6, inducer isopropylthio thiogalactoside (IPTG) induced expression is added in 4 hours, obtain
Obtain Escherichia coli intracellular expression recombinant protein；The Escherichia coli intracellular expression recombinant protein of above-mentioned acquisition is pure through conventional nickel column
Change, that is, obtain the antigen of the dual anti-former epitope of people's fibronectin type III structure domain views prepared using Escherichia coli production
Substitute.
The recombinant protein prepared using the above method is as the standard antigen substitute in ELISA detection kit.
Compared with prior art, beneficial effects of the present invention are：The method of the present invention can simply, it is quick, efficiently prepare tool
There is the antigen substitute of the double epitopes of displaying, to produce corresponding immunology detection standard items establishing techniques platform, the method
Synthesis recombinant protein is at low cost, the period is short, stability is high, technically easy to operate.
Description of the drawings
Fig. 1 is that (amino acid sequence is with English name single-letter for the amino acid sequence figures of the double epitopes of Fn3 of the present invention displaying
It represents)；In figure, 1) Fn3 amino acid sequences, 2) rFn3-2-epitopes amino acid sequences；
Fig. 2 is the expression vector structure chart of pET28-rFn3-2-epitopes of the present invention；
Fig. 3 is coomassie brilliant blue staining and Western blot western blots detection recombinant protein rFn3-2- of the present invention
Epitopes is expressed；In figure, figure A is coomassie brilliant blue staining：1) pre-dyed Marker, 2) recombinant protein rFn3-2- after purification
epitopes；Figure B is Western blot western blots：1) list of the 12-21 amino acid residue epitopes of the anti-NT-proBNP in mouse source
Clonal antibody 13G12 (being purchased from Hy Test Ltd) detects recombinant protein, and 2) the 62-73 amino acid residues of the anti-NT-proBNP in mouse source
Monoclonal antibody 15C4 (being purchased from Hy Test Ltd) the detection recombinant proteins of epitope；
Fig. 4 is double antibody sandwich ELISA detection recombinant protein rFn3-2-epitopes of the present invention；For the anti-NT- in mouse source
The monoclonal antibody 13G12 and the 62-73 amino acid of the anti-NT-proBNP in mouse source of the 12-21 amino acid residue epitopes of proBNP are residual
The monoclonal antibody 15C4 double antibody sandwich ELISAs detection recombinant protein rFn3-2-epitopes of base table position.
Specific embodiment
Below in conjunction with the accompanying drawings and specific embodiment the present invention is further illustrated, but have no effect on the present invention guarantor
Protect range.
A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin, packet
Include following steps：
1. structure can be in the recombination of the dual anti-former epitope of III type structure domain views of expression in escherichia coli people fibronectin
Protein expression vector：
This step uses the amino acid epitope (NT-proBNP12-21 epitopes) of plasma pro-brain natriuretic peptide levels N-terminal 12-21 and brain sodium
The epitope (NT-proBNP62-73 epitopes) of the amino acid of peptide precursor N-terminal 62-73 is model, by genetic recombination, will be encoded
The base sequence of one of epitope replaces the base sequence in III type structural domain coding FG loop areas of people's fibronectin
(base sequence for encoding Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys), and another epitope will be encoded
Base sequence by encode SSNNNNNNNNNN (S represents serine residue, and N represents asparagine residue) small peptide be binned in
3 ' ends of upper gene；The base sequence of 6 histidine residues of coding is introduced at 5 ' ends, as label is isolated and purified, conveniently subsequently
Protein purification.It is introduced respectively for the restriction enzyme site Nco I of clone and Hind III at 5 ' ends and 3 ' ends simultaneously.It will compile above
On the fusion gene cloning to intracellular expression vector of Escherichia coli pET28 of the double epitopes of code Fn3 displayings, Escherichia coli cell is completed
The expression vector establishment of the interior double epitope recombinant proteins of expression Fn3 displayings.
2. the recombinant protein expression vector of structure is converted e. coli bl21 (DE3) competent cell, using containing
The LB solid medium flat screens of antibiotic select positive transformant.
3. induced expression based on the dual anti-former epitope gene recombinant protein of III type structure domain views of people's fibronectin and
Purifying：
The positive transformant that step 2 is filtered out is cultivated in LB fluid nutrient mediums to OD600nmDuring=0.4-0.6, add in
Inducer isopropylthio thiogalactoside (IPTG) induced expression 4 hours.In the process, Escherichia coli intracellular expression recombination egg
In vain.The recombinant protein of expression carries out affinity chromatography with the histidine tag of recombinant protein, is expressed through conventional ni-sepharose purification
Recombinant protein.
4. double antibody sandwich ELISA detection recombination egg is carried out with the antibody of anti-two shown epitopes respectively
In vain.
Embodiment 1
The structure of the III bis- epitope recombinant protein expression vectors of type structure domain views NT-proBNP of people's fibronectin
It builds：
The base sequence for encoding NT-proBNP12-21 amino acid residue epitopes is replaced to the alkali in coding Fn3FG loop areas
Basic sequence (base sequence for encoding Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys), will encode NT-
The base sequence of proBNP62-73 amino acid residue epitopes replaces the base sequence at the 3 ' ends of coding Fn3, to realize through people's fibre
The method that dimension III type structural domain of connection albumen stablizes the expression bis- antigen epitope genes of NT-proBNP.Encoding two small peptide bases
The base sequence of coding SSNNNNNNNNNN (S represents serine residue, and N represents asparagine residue) small peptide is introduced in sequence,
To extend the distance between two epitopes, reduce influencing each other between the two；It is residual that 6 group amino acid of coding are introduced at 5 ' ends
The base sequence of base isolates and purifies label as recombinant protein, facilitates subsequent protein purification；Simultaneously at 5 ' ends and 3 ' ends point
Not Yin Ru restriction enzyme site Nco I and Hind III for cloning.The fusion of coding recombinant protein rFn3-2-epitopes is obtained,
Amino acid sequence is shown in Fig. 1.
More than fusion restriction enzyme site Nco I and Hind III are building up on pET28 coli expression carriers, obtained
To recombinant expression carrier pET28-rFn3-2-epitopes, the recombinant protein of fusion can be in e. coli bl21 (DE3) bacterial strain
Intracellular expression is carried out, expression vector structure is shown in Fig. 2.
Embodiment 2
E. coli bl21 (DE3) converts：
Take 0.1 μ g recombinate after the heat-shock transformed 100 μ L e. coli bl21s (DE3) of plasmid pET28-rFn3-2-epitopes
Competent cell.Concrete operations are：After more than plasmid and Competent cell gently mixing, ice bath 3 minutes, then
Then 42 DEG C of heat shocks 80 seconds, ice bath 5 minutes add in 37 DEG C of 200 preheated μ L SOC culture mediums；37 DEG C of incubators are placed 30 minutes
Afterwards, in 37 DEG C, 220rpm shaken cultivations 1 hour；Take respectively 50 μ L, 100 μ L cultivate after bacterium solution gradient coated plate, used medium is
The LB solid mediums of antibiotic containing kanamycins (final concentration of 50 μ g/mL).It is incubated overnight, grows positive single in 37 DEG C of incubators
Clone.
Wherein, LB solid cultures based formulas is：Tryptone (Tryptone) 10g/L, yeast extract (Yeast
Extract) 5g/L, sodium chloride (NaCl) 10g/L, agar Icing Sugar 15g/L add ddH2O to be formulated, pH=7.2.
Embodiment 3
The induced expression of the III bis- epitope recombinant proteins of type structure domain views NT-proBNP of people's fibronectin：
The positive transformant obtained in embodiment 2 is containing kanamycins antibiotic (final concentration of 50 after picking monoclonal
μ g/mL) LB solid mediums on cross, be incubated overnight in 37 DEG C of incubators.Picking monoclonal is inoculated in be resisted containing kanamycins
In the 3mL LB fluid nutrient mediums of raw element (final concentration of 50 μ g/mL), 37 DEG C, 220rpm is incubated overnight.Next day, with 1:100
Bacterium solution is inoculated into the 500mL LB fluid nutrient mediums containing kanamycins antibiotic (final concentration of 50 μ g/mL) by ratio, and 37
DEG C, 220rpm cultivated to OD600nmReach 0.5.Then, the isopropylthiogalactoside (IPTG) of final concentration of 0.2mM is added,
Induced expression 4 hours under the conditions of 26 DEG C, 220rpm.In this process, Escherichia coli intracellular expression recombinant protein rFn3-2-
epitopes.Finally, in 4 DEG C, 5000rpm low-temperature centrifugations 10 minutes, the thalline containing recombinant protein is collected.
The formula of LB fluid nutrient mediums is：Tryptone (Tryptone) 10g/L, yeast extract (Yeast
Extract) 5g/L, sodium chloride (NaCl) 10g/L, adds ddH2O to be formulated, pH=7.2.
LB solid culture based formulas is：Tryptone (Tryptone) 10g/L, yeast extract (Yeast extract)
5g/L, sodium chloride (NaCl) 10g/L, agar Icing Sugar 15g/L add ddH2O to be formulated, pH=7.2.
By above-mentioned induced expression, the Escherichia coli of high-level intracellular expression recombinant protein rFn3-2-epitopes are obtained
BL21(DE3)。
Embodiment 4
The III type structure domain views bis- epitope recombinant proteins of NT-proBNP of people's fibronectin isolate and purify：
It is broken by ultrasound by the e. coli bl21 (DE3) of the high-level intracellular expression recombinant protein of gained in embodiment 3
The methods of broken, low-temperature and high-speed centrifuges obtains the supernatant for including soluble protein, carries out ni-sepharose purification.
With 10 column volumes of equilibration buffer nickel column, low speed upper prop after above-mentioned gained supernatant is balanced.On sample
After column, continue to wash 20 column volumes with the buffer solution of 20mM imidazole concentrations, then respectively with containing 40,60,80,100,
120th, 240, the buffer solution of 500mM imidazole concentrations carries out gradient elution, collects eluent, that is, obtains recombinant protein after purification.
Expressing quantity is detected with SDS-PAGE, and whether is recombinant protein with the albumen of Western blot western blots detection expression
rFn3-2-epitopes.Testing result is shown in Fig. 3.
Recombinant protein rFn3-2-epitopes after purification uses desalting column desalination, -20 DEG C of Cord bloods.
Embodiment 5
The double-antibody sandwich of the III bis- epitope recombinant proteins of type structure domain views NT-proBNP of people's fibronectin
ELISA method detection：
By the recombinant protein rFn3-2-epitopes after desalination, protein concentration is measured by BCA methods.
With the monoclonal antibody for the anti-NT-proBNP62-73 amino acid residues epitope in mouse source that Hy Test Ltd companies produce
15C4 is as capture antibody (antibody 1:2000 dilutions, 3.5 μ g/mL of final concentration), it is coated with 3 hours in 37 DEG C in 96 hole elisa Plates；
5%BSA is closed overnight as confining liquid；Then add the recombinant protein rFn3-2-epitopes of gradient dilution respectively, 37 DEG C altogether
It is incubated 2 hours, and to be coated with buffer solution as blank control group, every group is done three parallel holes；Respectively plus Hy Test Ltd companies
The monoclonal antibody 13G12 of the anti-NT-proBNP12-21 amino acid residues epitope in mouse source of the horseradish peroxidase label of production makees
To detect antibody (1:2000 dilutions, 0.35 μ g/mL of final concentration), 37 DEG C are incubated 2 hours altogether.Then through PBST cleaning solutions hole flushing 5
After secondary, finally plus substrate TMB develops the color 10 minutes, is terminated with the sulfuric acid of 2M, optical density OD values are read at wavelength 450nm.With institute
OD values are made and protein concentration graph of relation, obtain recombinant protein rFn3-2-epitopes and monoclonal antibody 15C4 and 13G12
Double-antibody sandwich elisa examination criteria curve.See Fig. 4.
After above step has been coated with antibody, confining liquid and albumen every time, all with PBST cleaning solution hole flushings.
The PBST washs formula of liquid：Sodium chloride (NaCl) 8g/L, potassium dihydrogen phosphate (KH2PO4) 0.27g/L, phosphoric acid hydrogen
Disodium (Na2HPO4) 1.42g/L, potassium chloride (KCl) 0.2g/L, Tween-20 (Tween-20) 0.05% adds deionized water to prepare
It forms, pH=7.4.
From the above, it is seen that the present invention mainly has following outstanding feature：In III type structural domain of people's fibronectin
(Fn3) gene order of the bis- epitopes of NT-proBNP can be expressed by being introduced on, and is passed through intracellular expression vector of Escherichia coli and existed
The stabilization recombinant protein rFn3-2-epitopes of high expression is obtained in Escherichia coli body.
From the point of view of above example, this method can quickly, efficiently obtain the weight that can express the bis- epitopes of NT-proBNP
Histone, the detection method establishing techniques platform for further research NT-proBNP.
Embodiment of the present invention is without being limited thereto, the above according to the present invention, according to the ordinary technical knowledge of this field
And universal method, under the premise of the above-mentioned basic fundamental thought of the present invention is not departed from, the present invention can also have other embodiments.
Other epitopes or other eggs of NT-proBNP can be such as introduced on III type structural domain (Fn3) of people's fibronectin
White matter class epitope.Therefore, the present invention can also make the modification, replacement or change of other diversified forms, all fall within this hair
Within bright rights protection scope.
Sequence table
<110>University Of Dalian
<120>A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 273
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 1
cgtgacctgg aagtggtcgc tgccacaccg acgagtctgc tgatttcttg ggatgcacca 60
gctgtaaccg tgcgctacta ccgcattact tacggggaga cgggcggcaa ttccccggtg 120
caagaattta ctgttccggg cagcaaaagt acagcaacta ttagcggcct gaaaccgggc 180
gttgattata ccattactgt ttacgcagta actgggcgtg gcgattcacc ggcgtcctct 240
aaacctattt cgatcaacta tcgtactgaa atc 273
<210> 2
<211> 441
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
ccatggcaca tcatcatcat catcacggcg gcggcgcaca agtttctgac gttccgcgcg 60
atctggaagt tgttgcagca accccgacca gtctgctgat tagttgggac gcaccggcag 120
ttaccgttcg ctattatcgc attacctacg gcgaaaccgg cggtaatagt ccggttcagg 180
aatttaccgt tccgggtagt aaaagcaccg caaccattag cggtctgaaa ccgggcgttg 240
attacaccat taccgtttac gcggttaccg gtctggaaac ctctggtctg caagaacaac 300
gtagcccgat cagcattaat tatcgtacct cgtcaaacaa taataataat aataataata 360
ataatcgcgg tcatcgtaaa atggtcctgt acaccctgcg caaaaaaggc aaaggcaaaa 420
aaggcaaata ataacaagct t 441
<210> 3
<211> 5681
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 3
tggcgaatgg gacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg 60
cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc 120
ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg 180
gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc 240
acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt 300
ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggtctattc 360
ttttgattta taagggattt tgccgatttc ggcctattgg ttaaaaaatg agctgattta 420
acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaatttcag gtggcacttt 480
tcggggaaat gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta 540
tccgctcatg aattaattct tagaaaaact catcgagcat caaatgaaac tgcaatttat 600
tcatatcagg attatcaata ccatattttt gaaaaagccg tttctgtaat gaaggagaaa 660
actcaccgag gcagttccat aggatggcaa gatcctggta tcggtctgcg attccgactc 720
gtccaacatc aatacaacct attaatttcc cctcgtcaaa aataaggtta tcaagtgaga 780
aatcaccatg agtgacgact gaatccggtg agaatggcaa aagtttatgc atttctttcc 840
agacttgttc aacaggccag ccattacgct cgtcatcaaa atcactcgca tcaaccaaac 900
cgttattcat tcgtgattgc gcctgagcga gacgaaatac gcgatcgctg ttaaaaggac 960
aattacaaac aggaatcgaa tgcaaccggc gcaggaacac tgccagcgca tcaacaatat 1020
tttcacctga atcaggatat tcttctaata cctggaatgc tgttttcccg gggatcgcag 1080
tggtgagtaa ccatgcatca tcaggagtac ggataaaatg cttgatggtc ggaagaggca 1140
taaattccgt cagccagttt agtctgacca tctcatctgt aacatcattg gcaacgctac 1200
ctttgccatg tttcagaaac aactctggcg catcgggctt cccatacaat cgatagattg 1260
tcgcacctga ttgcccgaca ttatcgcgag cccatttata cccatataaa tcagcatcca 1320
tgttggaatt taatcgcggc ctagagcaag acgtttcccg ttgaatatgg ctcataacac 1380
cccttgtatt actgtttatg taagcagaca gttttattgt tcatgaccaa aatcccttaa 1440
cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttcttga 1500
gatccttttt ttctgcgcgt aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg 1560
gtggtttgtt tgccggatca agagctacca actctttttc cgaaggtaac tggcttcagc 1620
agagcgcaga taccaaatac tgtccttcta gtgtagccgt agttaggcca ccacttcaag 1680
aactctgtag caccgcctac atacctcgct ctgctaatcc tgttaccagt ggctgctgcc 1740
agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg 1800
cagcggtcgg gctgaacggg gggttcgtgc acacagccca gcttggagcg aacgacctac 1860
accgaactga gatacctaca gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga 1920
aaggcggaca ggtatccggt aagcggcagg gtcggaacag gagagcgcac gagggagctt 1980
ccagggggaa acgcctggta tctttatagt cctgtcgggt ttcgccacct ctgacttgag 2040
cgtcgatttt tgtgatgctc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg 2100
gcctttttac ggttcctggc cttttgctgg ccttttgctc acatgttctt tcctgcgtta 2160
tcccctgatt ctgtggataa ccgtattacc gcctttgagt gagctgatac cgctcgccgc 2220
agccgaacga ccgagcgcag cgagtcagtg agcgaggaag cggaagagcg cctgatgcgg 2280
tattttctcc ttacgcatct gtgcggtatt tcacaccgca tatatggtgc actctcagta 2340
caatctgctc tgatgccgca tagttaagcc agtatacact ccgctatcgc tacgtgactg 2400
ggtcatggct gcgccccgac acccgccaac acccgctgac gcgccctgac gggcttgtct 2460
gctcccggca tccgcttaca gacaagctgt gaccgtctcc gggagctgca tgtgtcagag 2520
gttttcaccg tcatcaccga aacgcgcgag gcagctgcgg taaagctcat cagcgtggtc 2580
gtgaagcgat tcacagatgt ctgcctgttc atccgcgtcc agctcgttga gtttctccag 2640
aagcgttaat gtctggcttc tgataaagcg ggccatgtta agggcggttt tttcctgttt 2700
ggtcactgat gcctccgtgt aagggggatt tctgttcatg ggggtaatga taccgatgaa 2760
acgagagagg atgctcacga tacgggttac tgatgatgaa catgcccggt tactggaacg 2820
ttgtgagggt aaacaactgg cggtatggat gcggcgggac cagagaaaaa tcactcaggg 2880
tcaatgccag cgcttcgtta atacagatgt aggtgttcca cagggtagcc agcagcatcc 2940
tgcgatgcag atccggaaca taatggtgca gggcgctgac ttccgcgttt ccagacttta 3000
cgaaacacgg aaaccgaaga ccattcatgt tgttgctcag gtcgcagacg ttttgcagca 3060
gcagtcgctt cacgttcgct cgcgtatcgg tgattcattc tgctaaccag taaggcaacc 3120
ccgccagcct agccgggtcc tcaacgacag gagcacgatc atgcgcaccc gtggggccgc 3180
catgccggcg ataatggcct gcttctcgcc gaaacgtttg gtggcgggac cagtgacgaa 3240
ggcttgagcg agggcgtgca agattccgaa taccgcaagc gacaggccga tcatcgtcgc 3300
gctccagcga aagcggtcct cgccgaaaat gacccagagc gctgccggca cctgtcctac 3360
gagttgcatg ataaagaaga cagtcataag tgcggcgacg atagtcatgc cccgcgccca 3420
ccggaaggag ctgactgggt tgaaggctct caagggcatc ggtcgagatc ccggtgccta 3480
atgagtgagc taacttacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa 3540
cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat 3600
tgggcgccag ggtggttttt cttttcacca gtgagacggg caacagctga ttgcccttca 3660
ccgcctggcc ctgagagagt tgcagcaagc ggtccacgct ggtttgcccc agcaggcgaa 3720
aatcctgttt gatggtggtt aacggcggga tataacatga gctgtcttcg gtatcgtcgt 3780
atcccactac cgagatatcc gcaccaacgc gcagcccgga ctcggtaatg gcgcgcattg 3840
cgcccagcgc catctgatcg ttggcaacca gcatcgcagt gggaacgatg ccctcattca 3900
gcatttgcat ggtttgttga aaaccggaca tggcactcca gtcgccttcc cgttccgcta 3960
tcggctgaat ttgattgcga gtgagatatt tatgccagcc agccagacgc agacgcgccg 4020
agacagaact taatgggccc gctaacagcg cgatttgctg gtgacccaat gcgaccagat 4080
gctccacgcc cagtcgcgta ccgtcttcat gggagaaaat aatactgttg atgggtgtct 4140
ggtcagagac atcaagaaat aacgccggaa cattagtgca ggcagcttcc acagcaatgg 4200
catcctggtc atccagcgga tagttaatga tcagcccact gacgcgttgc gcgagaagat 4260
tgtgcaccgc cgctttacag gcttcgacgc cgcttcgttc taccatcgac accaccacgc 4320
tggcacccag ttgatcggcg cgagatttaa tcgccgcgac aatttgcgac ggcgcgtgca 4380
gggccagact ggaggtggca acgccaatca gcaacgactg tttgcccgcc agttgttgtg 4440
ccacgcggtt gggaatgtaa ttcagctccg ccatcgccgc ttccactttt tcccgcgttt 4500
tcgcagaaac gtggctggcc tggttcacca cgcgggaaac ggtctgataa gagacaccgg 4560
catactctgc gacatcgtat aacgttactg gtttcacatt caccaccctg aattgactct 4620
cttccgggcg ctatcatgcc ataccgcgaa aggttttgcg ccattcgatg gtgtccggga 4680
tctcgacgct ctcccttatg cgactcctgc attaggaagc agcccagtag taggttgagg 4740
ccgttgagca ccgccgccgc aaggaatggt gcatgcaagg agatggcgcc caacagtccc 4800
ccggccacgg ggcctgccac catacccacg ccgaaacaag cgctcatgag cccgaagtgg 4860
cgagcccgat cttccccatc ggtgatgtcg gcgatatagg cgccagcaac cgcacctgtg 4920
gcgccggtga tgccggccac gatgcgtccg gcgtagagga tcgagatctc gatcccgcga 4980
aattaatacg actcactata ggggaattgt gagcggataa caattcccct ctagaaataa 5040
ttttgtttaa ctttaagaag gagatatacc atggcacatc atcatcatca tcacggcggc 5100
ggcgcacaag tttctgacgt tccgcgcgat ctggaagttg ttgcagcaac cccgaccagt 5160
ctgctgatta gttgggacgc accggcagtt accgttcgct attatcgcat tacctacggc 5220
gaaaccggcg gtaatagtcc ggttcaggaa tttaccgttc cgggtagtaa aagcaccgca 5280
accattagcg gtctgaaacc gggcgttgat tacaccatta ccgtttacgc ggttaccggt 5340
ctggaaacct ctggtctgca agaacaacgt agcccgatca gcattaatta tcgtacctcg 5400
tcaaacaata ataataataa taataataat aatcgcggtc atcgtaaaat ggtcctgtac 5460
accctgcgca aaaaaggcaa aggcaaaaaa ggcaaataat aacaagcttg cggccgcact 5520
cgagcaccac caccaccacc actgagatcc ggctgctaac aaagcccgaa aggaagctga 5580
gttggctgct gccaccgctg agcaataact agcataaccc cttggggcct ctaaacgggt 5640
cttgaggggt tttttgctga aaggaggaac tatatccgga t 5681
Claims (6)
1. a kind of method for preparing antigen substitute based on the dual anti-former epitope of III type structure domain views of people's fibronectin, special
Sign is, includes the following steps：
(1) by genetic recombination, structure can be in the III dual anti-original of type structure domain views of expression in escherichia coli people fibronectin
The recombinant protein expression vector of epitope；
(2) the recombinant protein expression vector built in step (1) is converted into colibacillus engineering strain, filters out positive transformants
Son；
(3) positive transformant for filtering out step (2) carries out expression and purity, recombinant protein needed for acquisition.
2. one kind prepares antigen based on the dual anti-former epitope of III type structure domain views of people's fibronectin and replaces as described in claim 1
For the method for object, which is characterized in that the method is further included carries out double-antibody sandwich to the recombinant protein that step (3) obtains
ELISA method detection.
3. one kind prepares antigen based on the dual anti-former epitope of III type structure domain views of people's fibronectin and replaces as described in claim 1
For the method for object, which is characterized in that step (1) detailed process is：The base sequence of coding for antigens epitope is replaced people's fiber to connect
Meet base sequence (the coding Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser- in III type structural domain of albumen coding FG loop areas
The base sequence of Lys), and will encode another epitope base sequence by encode SSNNNNNNNNNN small peptides be binned in
3 ' ends (S represents serine residue, and N represents asparagine residue) of upper gene；In 5 ' end recombination codings 6 of more than fusion
A histidine tag is identified and is isolated and purified for recombinant protein；More than fusion gene cloning to Escherichia coli intracellular is expressed
To get to recombinant protein expression vector on carrier.
4. one kind prepares antigen based on the dual anti-former epitope of III type structure domain views of people's fibronectin and replaces as described in claim 1
For the method for object, which is characterized in that the recombinant protein expression vector conversion colibacillus engineering strain obtained in step (2), it should
Positive transformant is selected with the LB solid medium flat screens containing antibiotic.
5. one kind prepares antigen based on the dual anti-former epitope of III type structure domain views of people's fibronectin and replaces as described in claim 1
For the method for object, which is characterized in that step (3) detailed process is：The positive transformant that step (2) is filtered out, in LB liquid
It is cultivated in culture medium to OD600nmWhen=0.4~0.6, it is small to add in inducer isopropylthio thiogalactoside (IPTG) induced expression 4
When, obtain Escherichia coli intracellular expression recombinant protein；The Escherichia coli intracellular of above-mentioned acquisition is expressed into recombinant protein through conventional nickel
Column purification, recombinant protein needed for acquisition.
6. antigen substitute prepared by claim 1 the method is as the standard antigen substitute in ELISA detection kit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711469025.6A CN108179152A (en) | 2017-12-29 | 2017-12-29 | A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711469025.6A CN108179152A (en) | 2017-12-29 | 2017-12-29 | A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108179152A true CN108179152A (en) | 2018-06-19 |
Family
ID=62548718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711469025.6A Pending CN108179152A (en) | 2017-12-29 | 2017-12-29 | A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108179152A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110358785A (en) * | 2019-07-29 | 2019-10-22 | 大连大学 | The preparation method of the double epitopes of N- akrencephalon pro-BNP is shown based on class elastin laminin |
| WO2020015677A1 (en) * | 2018-07-17 | 2020-01-23 | 上海一宸医药科技有限公司 | Long-acting fibronectin type iii domain fusion protein |
| CN111748035A (en) * | 2020-05-20 | 2020-10-09 | 科稷达隆生物技术有限公司 | Novel FN3 antibody mutant and application thereof |
| CN112014566A (en) * | 2019-05-28 | 2020-12-01 | 上海奥普生物医药股份有限公司 | Amino-terminal brain natriuretic peptide precursor detection kit, preparation method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102887943A (en) * | 2012-08-30 | 2013-01-23 | 重庆业为基生物科技有限公司 | B cell epitope peptide segment of amino-terminal pro-brain natriuretic peptide and applications thereof |
| CN105671068A (en) * | 2016-03-15 | 2016-06-15 | 大连大学 | Method for preparing brain natriuretic peptide precursor antigen substitute based on human-derived skeleton protein Fn3 |
| CN106222189A (en) * | 2016-09-06 | 2016-12-14 | 大连大学 | A kind of method based on class elastin laminin label preparation restructuring N akrencephalon pro-BNP |
| CN106520820A (en) * | 2016-10-20 | 2017-03-22 | 大连大学 | Method for preparing pro-brain natriuretic peptide epitope by virtue of Bacillus brevis (B.brevis) |
-
2017
- 2017-12-29 CN CN201711469025.6A patent/CN108179152A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102887943A (en) * | 2012-08-30 | 2013-01-23 | 重庆业为基生物科技有限公司 | B cell epitope peptide segment of amino-terminal pro-brain natriuretic peptide and applications thereof |
| CN105671068A (en) * | 2016-03-15 | 2016-06-15 | 大连大学 | Method for preparing brain natriuretic peptide precursor antigen substitute based on human-derived skeleton protein Fn3 |
| CN106222189A (en) * | 2016-09-06 | 2016-12-14 | 大连大学 | A kind of method based on class elastin laminin label preparation restructuring N akrencephalon pro-BNP |
| CN106520820A (en) * | 2016-10-20 | 2017-03-22 | 大连大学 | Method for preparing pro-brain natriuretic peptide epitope by virtue of Bacillus brevis (B.brevis) |
Non-Patent Citations (3)
| Title |
|---|
| KARINA R SEFERIAN ET AL: "Immunodetection of glycosylated NT-proBNP circulating in human blood", 《CLIN CHEM》 * |
| 张德华: "《蛋白质与酶工程》", 30 September 2015, 合肥工业大学出版社 * |
| 李梦阳 等: "人源骨架蛋白FN3展示脑钠肽前体N端抗原表位研究", 《上海交通大学学报（医学版）》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020015677A1 (en) * | 2018-07-17 | 2020-01-23 | 上海一宸医药科技有限公司 | Long-acting fibronectin type iii domain fusion protein |
| CN110724198A (en) * | 2018-07-17 | 2020-01-24 | 上海一宸医药科技有限公司 | Long-acting fibronectin type III domain fusion proteins |
| CN112955474A (en) * | 2018-07-17 | 2021-06-11 | 上海一宸医药科技有限公司 | Long-acting fibronectin type III domain fusion proteins |
| US20210300995A1 (en) * | 2018-07-17 | 2021-09-30 | Shanghai Yichen Biomed Co. Ltd | Long-acting fibronectin type III domain fusion protein |
| CN110724198B (en) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | Long acting fibronectin type III domain fusion proteins |
| CN112014566A (en) * | 2019-05-28 | 2020-12-01 | 上海奥普生物医药股份有限公司 | Amino-terminal brain natriuretic peptide precursor detection kit, preparation method and application |
| CN110358785A (en) * | 2019-07-29 | 2019-10-22 | 大连大学 | The preparation method of the double epitopes of N- akrencephalon pro-BNP is shown based on class elastin laminin |
| CN111748035A (en) * | 2020-05-20 | 2020-10-09 | 科稷达隆生物技术有限公司 | Novel FN3 antibody mutant and application thereof |
| CN111748035B (en) * | 2020-05-20 | 2022-03-04 | 科稷达隆(北京)生物技术有限公司 | Novel FN3 antibody mutant and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111304232B (en) | Method for purifying protein based on membrane surface fusion expression strategy and application thereof | |
| CN108179152A (en) | A kind of method that antigen substitute is prepared based on the dual anti-former epitope of III type structure domain views of people's fibronectin | |
| CN111850007B (en) | Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application | |
| CN110343708A (en) | A kind of pumpkin aphid passes the preparation of yellow viral movement protein purifying expression and its polyclonal antibody | |
| CN111848758B (en) | Cellulosome docking protein mutant suitable for low calcium ion concentration and application | |
| CN110331156B (en) | anti-Mical 2 polyclonal antibody and preparation method thereof | |
| CN107739404A (en) | A kind of protectiveness people PrPC G127I mutant and its construction method | |
| CN115074340B (en) | Novel intein and application thereof in synthesis of human tropoelastin | |
| CN111848757B (en) | Cellulosome docking protein combined mutant 36862 suitable for low calcium ion concentration and application | |
| CN111850005B (en) | Cellulosome docking protein combined mutant 36863 suitable for low calcium ion concentration and application | |
| KR101842130B1 (en) | Transformed E. coli producing pili(F4, F18) and heat labile toxin(LT) for postweaing diarrhea vaccine in pigs and vaccine composition comprising the pili and LT produced by the same | |
| CN112592877B (en) | Recombinant escherichia coli for over-expressing lsrC gene and construction method and application thereof | |
| CN114774452A (en) | Construction method and application of engineering escherichia coli for adsorbing mercury ions in solution | |
| CN113383080B (en) | Bacterial expression vectors for increasing protein secretion | |
| CN114150002A (en) | Light-operated gene switch and application thereof | |
| CN111850006B (en) | Cellulosome docking protein combined mutant 36865 suitable for low calcium ion concentration and application | |
| CN110938645A (en) | Sugarcane yellow leaf virus motor protein expression and purification method and preparation of polyclonal antiserum thereof | |
| CN110885363A (en) | Expression and purification method of luffa aphid-borne yellowed virus motor protein and preparation of polyclonal antiserum thereof | |
| CN110596381A (en) | Method for detecting melon aphid-borne yellowed virus and preparation of special polyclonal antibody thereof | |
| KR20060098528A (en) | The expression and purification method of human protein tyrosine phosphatase using e.coli system | |
| CN111848759B (en) | Cellulosomal dockerin mutant 36741 with improved activity and application thereof | |
| CN111850004B (en) | Cellulosomal dockerin mutant 36740 with improved activity and application thereof | |
| CN109439680B (en) | Method for preparing antibacterial recombinant protein | |
| CN114591985B (en) | Mutant pectin lyase and application thereof | |
| CN113122561B (en) | Expression vector of membrane protein SohB and expression and purification method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180619 |
|
| RJ01 | Rejection of invention patent application after publication |